Related Experiment Video
Updated: Feb 5, 2026

Establishment and Genetic Manipulation of Murine Hepatocyte Organoids
Published on: February 12, 2022
[Effect of different genotypes of PNPLA3 I148M on hepatocyte proliferation]
1Department of Endocrinology, the Third Affiliated Hospital, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology, Guangzhou 510630, China.
Abstract:
Objective: To explore the influence of patatin-like phospholipase domain containing-3 (PNPLA3) wild type 148I/I and mutant type 148M/M on HepG2 cell proliferation and the relative mechanisms. Methods: HepG2 cell line stably overexpressing PNPLA3 148I/I, 148M/M and negative control (NC) were set up. Cell counting kit-8 (CCK8) assay was used to measure cell viability. Edu assay was used to determine the ability of cell proliferation. Western blot was used to detect the protein levels in the phosphatidylinositol 3-kinases (PI3K) pathway. Enzyme-linked immunosorbent assay (ELISA) was used to detect proliferation-related PNPLA3 metabolites[arachidonic acid (AA) and lysophosphatidic acid (LPA)]. Quantitative real-time PCR was used to detect the expression level of prostaglandin G/H synthase 2 (PTGS2) and proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) associated with PNPLA3. Results: The cell viability of overexpression of PNPLA3 148M/M group was about 1/3 times higher than that of overexpression of PNPLA3 148I/I group, and the difference was statistically significant[(98.02±1.29)% vs (71.51±2.89)%, P<0.001]. There was no significant difference between overexpression of PNPLA3 148M/M group and negative control group[(98.02±1.29)% vs (100±2.61)%, P=0.181]. The proliferative activity of overexpression of PNPLA3 148M/M group was about 1/3 times higher than that of overexpression of PNPLA3 148I/I group, and the difference was statistically significant(46.46±1.83 vs 35.96±2.65, P=0.001). There was no significant difference between overexpression of PNPLA3 148M/M group and negative control group(46.46±1.83 vs 46.64±7.33, P=0.965). The PGC1α mRNA expression, total PI3K, PThr-308AKT, PSer2448-mammalian target of rapamycin (PSer2448-mTOR) and PGC1α protein expression levels in the overexpression of PNPLA3 148M/M group were higher than those in the overexpression of PNPLA3 148I/I group, but there were no significant differences in AA and LPA levels, as well as PTGS2 mRNA expression levels. Conclusion: PNPLA3 148M/M cell proliferation was stronger than PNPLA3 148I/I.
Insights
The patatin-like phospholipase domain containing-3 (PNPLA3) 148M/M variant significantly enhances HepG2 cell proliferation compared to the 148I/I variant. This suggests PNPLA3 genotype influences cell growth through specific molecular pathways.
Area of Science:
- Hepatology
- Molecular Biology
- Cell Biology
Background:
- The patatin-like phospholipase domain containing-3 (PNPLA3) gene is strongly associated with liver disease severity.
- Understanding the functional impact of PNPLA3 variants, such as 148I/I and 148M/M, on liver cell behavior is crucial.
Purpose of the Study:
- To investigate the differential effects of PNPLA3 wild type (148I/I) and mutant (148M/M) variants on HepG2 cell proliferation.
- To elucidate the underlying molecular mechanisms influenced by these PNPLA3 variants.
Main Methods:
- Established HepG2 cell lines overexpressing PNPLA3 148I/I, 148M/M, and a negative control (NC).
- Assessed cell viability using Cell Counting Kit-8 (CCK8) and proliferation using Edu assay.
- Analyzed protein levels in the phosphatidylinositol 3-kinases (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway via Western blot.
- Quantified PNPLA3 metabolites (arachidonic acid and lysophosphatidic acid) using ELISA and gene expression of PTGS2 and PGC1α via qPCR.
Main Results:
- HepG2 cells overexpressing PNPLA3 148M/M exhibited significantly higher cell viability and proliferation rates compared to those overexpressing PNPLA3 148I/I.
- The PNPLA3 148M/M group showed increased expression of PGC1α, total PI3K, phosphorylated AKT (PThr-308AKT), and phosphorylated mTOR (PSer2448-mTOR).
- No significant differences were observed in arachidonic acid, lysophosphatidic acid, or PTGS2 mRNA levels between the groups.
Conclusions:
- The PNPLA3 148M/M variant promotes greater HepG2 cell proliferation than the PNPLA3 148I/I variant.
- The PI3K/AKT/mTOR pathway and PGC1α expression are likely involved in mediating the proliferative effects of the PNPLA3 148M/M variant.
Related Concept Videos
Abnormal Proliferation
Cells Coordinate Growth and Proliferation
Cell Specific Gene Expression
Genetic Lingo
Hardy-Weinberg Principle
Punnett Squares

